Skip to content
HQ Baseline logoHQ Baseline

Future of brain health

The Future of Baseline Testing: From Annual Check-Ups to Continuous Cognitive Monitoring

Reactive detection. Predictive identification. Preventive action. The evolution of baseline testing.

6 min read

The future of baseline testing is not an annual test. It’s continuous cognitive health monitoring — a fundamental transformation in how we understand and protect brain function.

Wearable cognitive tracking

Consumer wearable devices are beginning to incorporate daily cognitive metrics alongside the step counts and heart rate data they already collect. Reaction time tests, attention tasks, and processing speed challenges could be integrated into morning routines or smartphone interactions — providing continuous streams of cognitive data that detect subtle changes weeks or months before they’d appear on an annual baseline test. Research groups at universities including Stanford and MIT are exploring passive cognitive monitoring through typing patterns, screen interaction dynamics, and speech analysis.

Smart impact sensing

Instrumented mouthguards — already in use in professional rugby, the NFL, and military paratrooper training, as reported by MIT Technology Review and Frontiers in Bioengineering and Biotechnology— are logging cumulative head impact exposure throughout entire seasons. The Prevent Impact Monitor Mouthguard, developed from technology at the Cleveland Clinic, transmits real-time impact data to sideline iPads. Future iterations will integrate impact data with cognitive performance data, alerting coaches and medical staff when an athlete’s cumulative exposure reaches concerning thresholds — even in the absence of a diagnosed concussion.

Blood and fluid biomarkers

Abbott’s FDA-cleared GFAP/UCH-L1 blood test represents the first generation of point-of-care brain biomarker testing. Future development may yield biomarker panels that detect subconcussive damage before symptoms appear, establish individualized biochemical baselines that complement cognitive and functional baselines, and monitor recovery at the molecular level rather than relying solely on behavioral assessment. Research on saliva-based microRNA biomarkers, published in the British Journal of Sports Medicine, is exploring non-invasive alternatives that could be deployed in field settings. See also our piece on Abbott’s 15-minute blood test.

AI integration

Artificial intelligence will increasingly serve as the integrative layer — combining cognitive test data, balance metrics, eye tracking measurements, impact sensor data, biomarker levels, sleep patterns, and symptom reports into composite risk scores that predict injury vulnerability and recovery trajectory with precision no individual tool can achieve. The era of the annual paper-and-computer baseline will evolve into continuous, passive, multi-modal brain health surveillance. See also what AI is actually doing in brain injury assessment.

What we’re building

This is the vision we’re working toward at Headquarters. The annual baseline will always matter — it provides the structured, comprehensive snapshot that clinical decision-making requires. But layered on top of it will be a continuous stream of brain health data that transforms concussion management from reactive (detecting injury after it occurs) to predictive (identifying risk before injury happens) and ultimately preventive (modifying exposure based on individualized vulnerability data).

Your brain is the most important organ you have. It deserves more than a once-a-year check-in. At Headquarters, we’re building the future of brain health assessment — one baseline at a time.

Frequently asked questions

FAQ

What's changing about baseline testing?
The future is continuous cognitive health monitoring — wearables, mouthguards, blood biomarkers, and AI integration alongside the annual baseline.
Will the annual baseline disappear?
No. The annual baseline provides the structured, comprehensive snapshot clinical decision-making requires. But it will be layered with continuous passive data.
What about blood biomarkers?
Abbott's FDA-cleared GFAP/UCH-L1 test is the first generation. Future biomarker panels may detect subconcussive damage before symptoms appear and establish individualized biochemical baselines.
How does AI fit in?
AI will increasingly serve as the integrative layer — combining cognitive, balance, eye tracking, impact, biomarker, sleep, and symptom data into composite risk scores.

The future of brain health, one baseline at a time.

From annual snapshots to continuous monitoring — built on the foundation of a rigorous baseline today.